{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:03:07Z","timestamp":1771027387109,"version":"3.50.1"},"reference-count":123,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.cpcardiol.2024.102922","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T21:43:02Z","timestamp":1731102182000},"page":"102922","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The future of hypertension pharmacotherapy: Ongoing and future clinical trials for hypertension"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0447-7186","authenticated-orcid":false,"given":"Taha","family":"Mansoor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"Farrukh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subaina N.","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitry","family":"Abramov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin D.","family":"Michos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anurag","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timir K.","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sourbha S.","family":"Dani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Al Rifai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arunima","family":"Misra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay","family":"Nambi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salim S.","family":"Virani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul Mannan Khan","family":"Minhas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2024.102922_bib0001","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"International society of hypertension global hypertension practice guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0002","first-page":"E13","volume":"71","author":"Whelton","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0003","article-title":"undefined. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative. Thelancet.comB Zhou, RM Carrillo-Larco, G Danaei, LM Riley, CJ Paciorek, GA Stevens","author":"Zhou","year":"2021","journal-title":"EW GreggThe Lancet, 2021\u2022thelancet.com"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0004","first-page":"1190","article-title":"Trends in blood pressure control among US adults with hypertension, 1999-2000 to 2017-2018","volume":"324","author":"Muntner","year":"2020","journal-title":"jamanetwork.com"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/1573402115666190416161116","article-title":"Secondary hypertension: novel insights","volume":"16","author":"Tziomalos","year":"2020","journal-title":"Curr Hypertens Rev"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0006","first-page":"106","article-title":"Efficacy and tolerability of Olmesartan, Telmisartan, and Losartan in patients of Stage I hypertension: a randomized, open-label study","volume":"8","author":"Kalikar","year":"2017","journal-title":"J Pharmacol Pharmacother"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0007","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/jch.14536","article-title":"Comparative efficacy and safety of fimasartan in patients with hypertension: a network meta-analysis of randomized controlled trials","volume":"24","author":"Seo","year":"2022","journal-title":"The Journal of Clinical Hypertension"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0008","doi-asserted-by":"crossref","first-page":"6227","DOI":"10.4103\/jfmpc.jfmpc_787_22","article-title":"Blood pressure-lowering effect of telmisartan compared to losartan among mild to moderate essential hypertensive adult subjects: a meta-analysis","volume":"11","author":"Kumari","year":"2022","journal-title":"J Family Med Prim Care"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0009","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.mce.2008.06.006","article-title":"Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism","volume":"302","author":"Van Liefde","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0010","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/1824621","article-title":"Azilsartan: current evidence and perspectives in management of hypertension","author":"Pradhan","year":"2019","journal-title":"Int J Hypertens"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0011","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/08037051.2017.1412797","article-title":"A phase III, open-label, multicenter study to evaluate the safety and efficacy of long-term triple combination therapy with azilsartan, amlodipine, and hydrochlorothiazide in patients with essential hypertension","volume":"27","author":"Rakugi","year":"2018","journal-title":"Blood Press"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0012","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/10641963.2013.810228","article-title":"A comparative study on the effectiveness of losartan\/hydrochlorothiazide and telmisartan\/hydrochlorothiazide in patients with hypertension","volume":"36","author":"Hamada","year":"2014","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0013","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.2165\/00003495-200969090-00008","article-title":"Losartan\/hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy","volume":"69","author":"Keating","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0014","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1517\/17425250903282799","article-title":"Clinical experience in treating hypertension with fixed-dose combination therapy: angiotensin II receptor blocker losartan plus hydrochlorothiazide","volume":"5","author":"Abe","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0015","unstructured":"2023 ESH Hypertension Guideline update: bringing us closer together across the pond - American College of Cardiology. [Accessed 2024 June 24]. Available from: https:\/\/www.acc.org\/Latest-in-Cardiology\/Articles\/2024\/02\/05\/11\/43\/2023-ESH-Hypertension-Guideline-Update."},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0016","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/10641963.2017.1368536","article-title":"Losartan\/hydrochlorothiazide combination is safe and effective for morning hypertension in very-elderly patients","volume":"40","author":"Uchiwa","year":"2018","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0017","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/1753944712464285","article-title":"Combination therapy with losartan\/hydrochlorothiazide for blood pressure reduction and goal attainment in a real-world clinical setting in Japan","volume":"6","author":"Suzuki","year":"2012","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0018","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMe2215744","article-title":"Thiazide-like versus Thiazide diuretics - finally, an answer?","volume":"387","author":"Ingelfinger","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0019","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1517\/14656560902991514","article-title":"A randomized, comparative study evaluating the efficacy and tolerability of losartan-low dose chlorthalidone (6.25 mg) combination with losartan-hydrochlorothiazide (12.5 mg) combination in Indian patients with mild-to-moderate essential hypertension","volume":"10","author":"Pareek","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0020","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1161\/CIRCULATIONAHA.122.061029","article-title":"Hydrochlorothiazide versus chlorthalidone: what is the difference?","volume":"146","author":"Agarwal","year":"2022","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.cpcardiol.2024.102922_bib0021","article-title":"Comparison of the effectiveness and safety of chlorthalidone and hydrochlorothiazide in patients with hypertension: a meta-analysis","volume":"15","author":"Khenhrani","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0022","first-page":"508","article-title":"Benefit of treatment based on indapamide mostly combined with perindopril on mortality and cardiovascular outcomes: a pooled analysis of four trials","volume":"41","author":"Chalmers","year":"2023","journal-title":"J Hypertens"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0023","doi-asserted-by":"crossref","DOI":"10.1186\/s40885-022-00223-4","volume":"28","author":"Jeon","year":"2022","journal-title":"Clin Hypertens"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0024","article-title":"Efficacy and safety of nebivolol in hypertensive patients: a meta-analysis of randomized controlled trials","volume":"48","author":"Liu","year":"2020","journal-title":"J Int Med Res"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0025","article-title":"Efficacy and safety of bisoprolol compared to other selective beta-1 blockers in the treatment of hypertension: a systematic review and meta-analysis of randomized parallel clinical trials","volume":"42","author":"Jadhav","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0026","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/jch.14709","article-title":"Amlodipine in the current management of hypertension","volume":"25","author":"Wang","year":"2023","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0027","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jchf.2019.09.009","article-title":"Clinical phenogroups in heart failure with preserved ejection fraction: detailed phenotypes, prognosis, and response to spironolactone","volume":"8","author":"Cohen","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0028","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1097\/HJH.0000000000001219","article-title":"Efficacy and safety of sacubitril\/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy","volume":"35","author":"Wang","year":"2017","journal-title":"J Hypertens"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0029","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0030","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0031","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","article-title":"Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies","volume":"6","author":"Williams","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0032","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41440-020-00569-y","article-title":"Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone","volume":"44","author":"Rakugi","year":"2021","journal-title":"Hypertension Research"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0033","article-title":"Questions and answers-the four fundamental arguments on the new-born promising non-steroidal mineralocorticoid receptor antagonist","volume":"12","author":"L","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0034","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1161\/HYPERTENSIONAHA.119.13821","article-title":"Lysine-specific demethylase-1 deficiency increases agonist signaling via the mineralocorticoid receptor","volume":"75","author":"Treesaranuwattana","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0035","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","article-title":"Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD study","volume":"78","author":"Bakris","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0036","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/13543784.2021.1985462","article-title":"An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension","volume":"30","author":"Pitt","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0037","doi-asserted-by":"crossref","DOI":"10.1002\/cl2.1230","article-title":"PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open synthesis","volume":"18","author":"Haddaway","year":"2022","journal-title":"Campbell systematic reviews"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0038","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s12325-017-0511-1","article-title":"Fixed-dose triple combination of antihypertensive drugs improves blood pressure control: from clinical trials to clinical practice","volume":"34","author":"Mazza","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0039","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone synthase inhibition with Lorundrostat for uncontrolled hypertension: the target-HTN randomized clinical trial","volume":"330","author":"Laffin","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0040","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of Baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0041","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41440-022-01070-4","article-title":"Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers","volume":"46","author":"Freeman","year":"2023","journal-title":"Hypertens Res"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0042","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0306-3623(98)00257-2","article-title":"New insights into its pharmacological actions","volume":"33","author":"Kalinowski","year":"1999","journal-title":"Gen Pharmacol"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0043","article-title":"Clinical PG-DUE and, 1988 undefined. Efficacy and tolerance of cicletanine, a new antihypertensive agent: overview of 1226 treated patients. europepmc.OrgT Tarrade, PH GuinotDrugs under experimental and Clinical research","author":"Tarrade","year":"2024","journal-title":"1988\u2022europepmc.org"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0044","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/15548627.2018.1530929","article-title":"Spermidine: a physiological autophagy inducer acting as an anti-aging vitamin in humans?","volume":"15","author":"Madeo","year":"2019","journal-title":"Autophagy"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0045","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/ajcn\/nqy102","article-title":"Higher spermidine intake is linked to lower mortality: a prospective population-based study","volume":"108","author":"Kiechl","year":"2018","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0046","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/15548627.2017.1280225","article-title":"Dietary spermidine for lowering high blood pressure","volume":"13","author":"Eisenberg","year":"2017","journal-title":"Autophagy"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0047","unstructured":"Simon Sedej A, Tobias Eisenberg A, Abdellatif M, Wallner M. Protovol (Version 3.1-updated 23MAY2020) Spermidine Anti-Hypertension Study (SMARTEST) effect of spermidine on arterial blood pressure in hypertensive patients."},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154459","article-title":"Efficacy and safety of Songling Xuemaikang capsule for essential hypertension: a systematic review and meta-analysis of randomized controlled trials","volume":"107","author":"Meng","year":"2022","journal-title":"Phytomedicine"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0049","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.121.007923","article-title":"Efficacy and safety of Chinese herbal medicine compared with Losartan for mild essential hypertension: a randomized, multicenter, double-blind, noninferiority trial","volume":"15","author":"Lai","year":"2022","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0050","first-page":"799","article-title":"Effect of Songlingxuemaikang on mild essential hypertension in patients: a randomized parallel-controlled study","volume":"41","author":"Zhu","year":"2021","journal-title":"J Tradit Chin Med"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0051","first-page":"282","article-title":"Late-breaking science abstracts and featured science abstracts from the American Heart Association's Scientific Sessions 2023 and Late-breaking abstracts in resuscitation science from the Resuscitation Science Symposium 2023","volume":"148","author":"Lincoff","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0052","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s13318-019-00573-9","article-title":"The nonclinical pharmacokinetics and prediction of Human pharmacokinetics of SPH3127, a novel direct renin inhibitor","volume":"45","author":"Zhang","year":"2020","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0053","doi-asserted-by":"crossref","first-page":"10882","DOI":"10.1021\/acs.jmedchem.2c00834","article-title":"Discovery of SPH3127: a novel, highly potent, and orally active direct renin inhibitor","volume":"65","author":"Iijima","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0054","doi-asserted-by":"crossref","first-page":"735.e1","DOI":"10.1016\/j.clinthera.2021.01.025","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of SPH3127: a phase I, randomized, double-blind, placebo-controlled trial","volume":"43","author":"Jing","year":"2021","journal-title":"Clin Ther"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gene.2015.06.029","article-title":"Atrial natriuretic peptide in cardiovascular biology and disease (NPPA)","volume":"569","author":"Song","year":"2015","journal-title":"Gene"},{"issue":"3","key":"10.1016\/j.cpcardiol.2024.102922_bib0056","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7453\/gahmj.2014.017","article-title":"The unexpected uses of urso- and tauroursodeoxycholic acid in the treatment of non-liver diseases","volume":"3","author":"Vang","year":"2014","journal-title":"Glob Adv Health Med"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0057","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.neurobiolaging.2014.08.034","article-title":"Amyloid-\u03b2 pathology is attenuated by tauroursodeoxycholic acid treatment in APP\/PS1 mice after disease onset","volume":"36","author":"Dion\u00edsio","year":"2015","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0058","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1006\/bbrc.2001.4370","article-title":"Amyloid \u03b2-peptide disrupts mitochondrial membrane lipid and protein structure: protective role of tauroursodeoxycholate","volume":"281","author":"Rodrigues","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0059","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1006\/exnr.2001.7755","article-title":"A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease","volume":"171","author":"Keene","year":"2001","journal-title":"Exp Neurol"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0060","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11596-013-1095-x","article-title":"Efficacy and safety of tauroursodeoxycholic acid in the treatment of liver cirrhosis: a double-blind randomized controlled trial","volume":"33","author":"Pan","year":"2013","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0061","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.2337\/db10-0308","article-title":"Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women","volume":"59","author":"Kars","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0062","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2208391","article-title":"Zilebesiran, an RNA interference therapeutic agent for hypertension","volume":"389","author":"Desai","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0063","doi-asserted-by":"crossref","DOI":"10.1097\/CRD.0000000000000645","article-title":"Zilebesiran: a promising antihypertensive therapy inhibiting angiotensinogen synthesis","author":"Khan","year":"2024","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0064","first-page":"61","article-title":"Colchicine in cardiovascular disease: In-depth review","volume":"145","author":"Deftereos","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0065","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1111\/bcp.15688","article-title":"Colchicine enhances \u03b2 adrenoceptor-mediated vasodilation in men with essential hypertension","volume":"89","author":"Ehlers","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0066","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.amjcard.2021.07.004","article-title":"Potential of minocycline for treatment of resistant hypertension","volume":"156","author":"Pepine","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0067","doi-asserted-by":"crossref","DOI":"10.1161\/hyp.68.suppl_1.p110","article-title":"Abstract P110: low dose minocycline lowers BP and improves inflammatory status in patients with treatment resistant hypertension","volume":"68","author":"Qi","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0068","unstructured":"Abstract 15921: antihypertensive effects of minocycline are associated with improvement of inflammatory status in patients with treatment resistant hypertension | circulation. [Accessed 2024 June 25]. Available from: https:\/\/www.ahajournals.org\/doi\/abs\/10.1161\/circ.134.suppl_1.15921."},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0069","doi-asserted-by":"crossref","DOI":"10.1152\/ajpheart.00107.2006","article-title":"Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy","volume":"291","author":"Belluardo","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0070","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40292-021-00483-5","article-title":"The natriuretic peptides for hypertension treatment","volume":"29","author":"Rubattu","year":"2022","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0071","doi-asserted-by":"crossref","first-page":"E67","DOI":"10.1161\/CIR.0000000000000558","article-title":"Heart disease and stroke statistics - 2018 update: a report from the American Heart Association","volume":"137","author":"Benjamin","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0072","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1161\/HYPERTENSIONAHA.121.18298","article-title":"Racial differences in XO (Xanthine Oxidase) and mitochondrial DNA damage-associated molecular patterns in resistant hypertension","volume":"79","author":"Butts","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0073","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.amjcard.2011.06.054","article-title":"Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease","volume":"108","author":"Micha","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0074","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0075","doi-asserted-by":"crossref","DOI":"10.1186\/ar2045","article-title":"Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study","volume":"8","author":"van Halm","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0076","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/rheumatology\/kem169","article-title":"Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis","volume":"46","author":"Panoulas","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0077","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s10067-009-1208-x","article-title":"Does TNF-alpha blockade play any role in cardiovascular risk among rheumatoid arthritis (RA) patients?","volume":"28","author":"Cuchacovich","year":"2009","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0078","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0033-0620(98)80019-4","article-title":"The cardiac toxicity of anabolic steroids","volume":"41","author":"Sullivan","year":"1998","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0079","article-title":"hypertension HM-J of, 1989 undefined. Sex steroid hormones are altered in essential hypertension. Journals.Lww.ComGS Hughes, RS Mathur, HS MargoliusJournal of hypertension","author":"Hughes","year":"2024","journal-title":"1989\u2022journals.lww.com"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0080","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/00004872-199307000-00003","article-title":"Sex hormones and hemostatic risk factors for coronary heart disease in men with hypertension","volume":"11","author":"Phillips","year":"1993","journal-title":"J Hypertens"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0081","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1524-6175.2005.04133.x","article-title":"Transdermal clonidine: therapeutic considerations","volume":"7","author":"Sica","year":"2005","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0082","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/HYPERTENSIONAHA.121.14519","article-title":"Circadian rhythm, clock genes, and hypertension: recent advances in hypertension","volume":"78","author":"Costello","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0083","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1093\/eurheartj\/ehz754","article-title":"Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial","volume":"41","author":"Hermida","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0084","unstructured":"Treatment in morning versus evening - American College of Cardiology. [Accessed 2024 June 19]. Available from: https:\/\/www.acc.org\/Latest-in-Cardiology\/Clinical-Trials\/2022\/08\/25\/03\/27\/TIME."},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0085","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1161\/HYPERTENSIONAHA.116.07664","article-title":"Effects of magnesium supplementation on blood pressure: a meta-analysis of randomized double-blind placebo-controlled trials","volume":"68","author":"Zhang","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0086","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1684\/mrh.2013.0343","article-title":"Oral magnesium supplements decrease high blood pressure (SBP>155 mmHg) in hypertensive subjects on anti-hypertensive medications: a targeted meta-analysis","volume":"26","author":"Rosanoff","year":"2013","journal-title":"Magnes Res"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0087","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/ejcn.2012.4","article-title":"Effect of magnesium supplementation on blood pressure: a meta-analysis","volume":"66","author":"Kass","year":"2012","journal-title":"Eur J Clin Nutr"},{"issue":"20","key":"10.1016\/j.cpcardiol.2024.102922_bib0088","doi-asserted-by":"crossref","DOI":"10.3390\/nu14204396","article-title":"Effects of L-citrulline supplementation on endothelial function and blood pressure in hypertensive postmenopausal women","volume":"14","author":"Maharaj","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0089","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/18715222113139990008","article-title":"Effects of oral L-citrulline supplementation on lipoprotein oxidation and endothelial dysfunction in humans with vasospastic angina","volume":"13","author":"Morita","year":"2013","journal-title":"Immunol Endocr Metab Agents Med Chem"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0090","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/gme.0b013e3182733794","article-title":"Effects of watermelon supplementation on arterial stiffness and wave reflection amplitude in postmenopausal women","volume":"20","author":"Figueroa","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0091","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/ajh.2012.20","article-title":"Watermelon extract supplementation reduces ankle blood pressure and carotid augmentation index in obese adults with prehypertension or hypertension","volume":"25","author":"Figueroa","year":"2012","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0092","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ajh.2010.142","article-title":"Effects of watermelon supplementation on aortic blood pressure and wave reflection in individuals with prehypertension: a pilot study","volume":"24","author":"Figueroa","year":"2011","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0093","first-page":"1","article-title":"The contribution of sodium reduction and potassium increase to the blood pressure lowering observed in the Salt Substitute and Stroke Study","author":"Huang","year":"2024","journal-title":"Journal of Human Hypertension 2024"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0094","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijcard.2016.12.048","article-title":"The effect of potassium supplementation on blood pressure in hypertensive subjects: a systematic review and meta-analysis","volume":"230","author":"Filippini","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0095","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.jacc.2014.12.039","article-title":"Dietary sodium and health: more than just blood pressure","volume":"65","author":"Farquhar","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0096","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1249\/MSS.0b013e318194cc75","article-title":"Effects of amino acids supplement on physiological adaptations to resistance training","volume":"41","author":"Kraemer","year":"2009","journal-title":"Med Sci Sports Exerc"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0097","unstructured":"Study details | salt and HMB Study | ClinicalTrials.Gov. [Accessed 2024 June 25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05515900."},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0098","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1161\/HYPERTENSIONAHA.118.12150","article-title":"The multilayered interplay between fructose and salt in development of hypertension: what has been revealed so far","volume":"73","author":"Eren","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0099","doi-asserted-by":"crossref","first-page":"276","DOI":"10.5551\/jat.30000","article-title":"An update on nutrients and blood pressure: summary of INTERMAP Study findings","volume":"23","author":"Chan","year":"2016","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nu12010001","article-title":"Dietary sodium intake and risk of cardiovascular disease: a systematic review and dose-response meta-analysis","volume":"12","author":"Wang","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0101","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-03421-7","article-title":"Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults","volume":"9","author":"Martens","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0102","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.881703","article-title":"Nicotinamide riboside supplementation for treating elevated systolic blood pressure and arterial stiffness in midlife and older adults","volume":"9","author":"Freeberg","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0103","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2021-001715","article-title":"Vitamin K2-a neglected player in cardiovascular health: a narrative review","volume":"8","author":"Hariri","year":"2021","journal-title":"Open Heart"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0104","first-page":"24","article-title":"Highlighting the substantial body of evidence confirming the importance of vitamin K2 As A cardio-support nutrient, and how the right K2 makes all the difference","volume":"18","author":"Vik","year":"2019","journal-title":"Integr Med Clin J"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0105","article-title":"Vitamin K2 and the calcium paradox: how A little known Vitamin could save your life \u2014 Dr","year":"2024","journal-title":"Kate Rh\u00e9aume"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0106","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40620-019-00685-0","article-title":"Vitamin K effects in human health: new insights beyond bone and cardiovascular health","volume":"33","author":"Fusaro","year":"2020","journal-title":"J Nephrol"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0107","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113413","article-title":"Application of nanotechnology to herbal antioxidants as improved phytomedicine: an expanding horizon","volume":"153","author":"Mishra","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0108","doi-asserted-by":"crossref","first-page":"818","DOI":"10.3945\/jn.112.170233","article-title":"Inorganic nitrate and beetroot juice supplementation reduces blood pressure in adults: a systematic review and meta-analysis","volume":"143","author":"Siervo","year":"2013","journal-title":"J Nutr"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0109","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.freeradbiomed.2013.01.024","article-title":"Effect of dietary nitrate on blood pressure, endothelial function, and insulin sensitivity in type 2 diabetes","volume":"60","author":"Gilchrist","year":"2013","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0110","first-page":"3","article-title":"Riboflavin lowers blood pressure: a review of a novel gene-nutrient interaction","volume":"2","author":"Strain","year":"2015","journal-title":"Nutrition and Food Sciences Research"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0111","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mam.2016.10.002","article-title":"MTHFR genotype and blood pressure: a personalized approach to prevention and treatment of hypertension","volume":"53","author":"McNulty","year":"2017","journal-title":"Mol Aspects Med"},{"issue":"10","key":"10.1016\/j.cpcardiol.2024.102922_bib0112","doi-asserted-by":"crossref","DOI":"10.3390\/foods6100092","article-title":"Curcumin: a review of its\u2019 Effects on Human health","volume":"6","author":"Hewlings","year":"2017","journal-title":"Foods"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0113","doi-asserted-by":"crossref","first-page":"9183","DOI":"10.3390\/molecules20059183","article-title":"Curcumin, inflammation, and chronic diseases: how are they linked?","volume":"20","author":"He","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0114","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1021\/jf020728u","article-title":"Oxygen radical absorbing capacity of phenolics in blueberries, cranberries, chokeberries, and lingonberries","volume":"51","author":"Zheng","year":"2003","journal-title":"J Agric Food Chem"},{"issue":"13","key":"10.1016\/j.cpcardiol.2024.102922_bib0115","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.3390\/nu14132688","article-title":"Chokeberry (A. melanocarpa (Michx.) Elliott)-A natural product for metabolic disorders?","volume":"14","author":"Olechno","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0116","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.tifs.2019.05.006","article-title":"Black chokeberry (Aronia melanocarpa) and its products as potential health-promoting factors - an overview","volume":"89","author":"Sidor","year":"2019","journal-title":"Trends Food Sci Technol"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0117","first-page":"72","article-title":"Instant effects of peppermint essential oil on the physiological parameters and exercise performance","volume":"4","author":"Meamarbashi","year":"2014","journal-title":"Avicenna J Phytomed"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0118","unstructured":"TOTUM\u2022854: to reduce blood pressure - Valbiotis. [Accessed 2024 June 25]. Available from: https:\/\/www.valbiotis.com\/en\/totum-854-2\/."},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0119","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1111\/dom.14817","article-title":"TOTUM-63, a plant-based polyphenol-rich extract, improves glycaemic control in subjects with prediabetes or early stage newly-diagnosed type 2 diabetes in a randomized, double-blind, placebo-controlled trial","volume":"24","author":"Sirvent","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0120","article-title":"Roselle for hypertension in adults","volume":"11","author":"Pattanittum","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0121","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/ptr.1628","article-title":"Phytochemical, pharmacological and toxicological aspects of Hibiscus sabdariffa L.: a review","volume":"19","author":"Ali","year":"2005","journal-title":"Phytother Res"},{"issue":"6","key":"10.1016\/j.cpcardiol.2024.102922_bib0122","doi-asserted-by":"crossref","DOI":"10.3390\/nu11061431","article-title":"Potential factors influencing the effects of anthocyanins on blood pressure regulation in humans: a review","volume":"11","author":"Vendrame","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.cpcardiol.2024.102922_bib0123","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.biopha.2018.03.023","article-title":"A review on phytochemistry and therapeutic uses of Hibiscus sabdariffa L","volume":"102","author":"Riaz","year":"2018","journal-title":"Biomed Pharmacother"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280624005577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280624005577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T21:51:24Z","timestamp":1732744284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280624005577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":123,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0146280624005577"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102922","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The future of hypertension pharmacotherapy: Ongoing and future clinical trials for hypertension","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102922","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102922"}}